Journal of the American College of Cardiology最新文献

筛选
英文 中文
Myocarditis Around the World: Progress and Opportunity in Times of Dynamic Change. 世界各地的心肌炎:动态变化时代的进展与机遇。
IF 22.3 1区 医学
Journal of the American College of Cardiology Pub Date : 2026-10-13 DOI: 10.1016/j.jacc.2026.08.020
Tahir S Kafil, Lucas C Godoy, Amirhossein Poopak, Heidi Thao Ly Nguyen, Peter P Liu
{"title":"Myocarditis Around the World: Progress and Opportunity in Times of Dynamic Change.","authors":"Tahir S Kafil, Lucas C Godoy, Amirhossein Poopak, Heidi Thao Ly Nguyen, Peter P Liu","doi":"10.1016/j.jacc.2026.08.020","DOIUrl":"https://doi.org/10.1016/j.jacc.2026.08.020","url":null,"abstract":"","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":"88 15","pages":"1761-1763"},"PeriodicalIF":22.3,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149182613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
When Heart Failure Alerts Should Not Trigger Diuresis. 当心力衰竭警报不应该触发利尿。
IF 22.3 1区 医学
Journal of the American College of Cardiology Pub Date : 2026-10-13 Epub Date: 2026-08-26 DOI: 10.1016/j.jacc.2026.06.045
Xiang Zhou, Hongyan Liu, Zhengdong Hua
{"title":"When Heart Failure Alerts Should Not Trigger Diuresis.","authors":"Xiang Zhou, Hongyan Liu, Zhengdong Hua","doi":"10.1016/j.jacc.2026.06.045","DOIUrl":"10.1016/j.jacc.2026.06.045","url":null,"abstract":"","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":" ","pages":"e2469"},"PeriodicalIF":22.3,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148818731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Making Sarcopenic Obesity Actionable for Heart Failure Prevention. 使肌肉减少性肥胖可用于预防心力衰竭。
IF 22.3 1区 医学
Journal of the American College of Cardiology Pub Date : 2026-10-13 DOI: 10.1016/j.jacc.2026.07.049
Xiang Zhou, Hongyan Liu, Zhengdong Hua
{"title":"Making Sarcopenic Obesity Actionable for Heart Failure Prevention.","authors":"Xiang Zhou, Hongyan Liu, Zhengdong Hua","doi":"10.1016/j.jacc.2026.07.049","DOIUrl":"https://doi.org/10.1016/j.jacc.2026.07.049","url":null,"abstract":"","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":"88 15","pages":"e2473"},"PeriodicalIF":22.3,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149182526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In it for the Long Run: Health Status as a Lifetime Metric in Low-Risk Aortic Stenosis. 从长远来看:健康状况作为低风险主动脉瓣狭窄的终身指标。
IF 22.3 1区 医学
Journal of the American College of Cardiology Pub Date : 2026-10-06 Epub Date: 2026-08-26 DOI: 10.1016/j.jacc.2026.07.031
Amit N Vora, Matthew W Sherwood
{"title":"In it for the Long Run: Health Status as a Lifetime Metric in Low-Risk Aortic Stenosis.","authors":"Amit N Vora, Matthew W Sherwood","doi":"10.1016/j.jacc.2026.07.031","DOIUrl":"10.1016/j.jacc.2026.07.031","url":null,"abstract":"","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":" ","pages":"1701-1703"},"PeriodicalIF":22.3,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148818749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Estimating the Effects of MTEER in U.S. Practice: A Transportability Analysis of the COAPT Trial. 估计MTEER在美国实践中的效果:COAPT试验的可移植性分析。
IF 22.3 1区 医学
Journal of the American College of Cardiology Pub Date : 2026-10-06 Epub Date: 2026-06-03 DOI: 10.1016/j.jacc.2026.04.025
Christina Lalani, Neel Butala, Huaying Dong, Yang Song, Gregg W Stone, Michael J Mack, Bahira Shahim, Dhruv S Kazi, David J Cohen, Issa J Dahabreh, Robert W Yeh
{"title":"Estimating the Effects of MTEER in U.S. Practice: A Transportability Analysis of the COAPT Trial.","authors":"Christina Lalani, Neel Butala, Huaying Dong, Yang Song, Gregg W Stone, Michael J Mack, Bahira Shahim, Dhruv S Kazi, David J Cohen, Issa J Dahabreh, Robert W Yeh","doi":"10.1016/j.jacc.2026.04.025","DOIUrl":"10.1016/j.jacc.2026.04.025","url":null,"abstract":"<p><strong>Background: </strong>Although mitral transcatheter edge-to-edge repair (MTEER) was approved for secondary mitral regurgitation after the COAPT trial, findings of other MTEER trials have been mixed, raising questions about the applicability of the COAPT results to contemporary clinical practice.</p><p><strong>Objectives: </strong>We used transportability methods to estimate the treatment effects of COAPT trial interventions applied to 2 target populations: 1) trial-eligible patients representative of U.S. clinical practice; and 2) treatment-candidate patients with secondary mitral regurgitation representative of U.S. clinical practice, regardless of trial eligibility.</p><p><strong>Methods: </strong>We identified patients from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (TVT) Registry who were treated with MTEER for secondary mitral regurgitation from March 14, 2019 to September 30, 2023. To select trial-eligible individuals, we applied COAPT trial eligibility criteria to the TVT Registry sample. We used inverse odds of participation weighting to standardize patient-level COAPT data to the data distribution of each target population sample and estimated treatment-specific outcomes. The primary outcome was heart failure hospitalization at 2 years. We also examined 10 secondary outcomes, including all-cause death.</p><p><strong>Results: </strong>Our analyses included 614 COAPT trial patients and 15,275 TVT Registry patients, of which 7,289 were COAPT trial-eligible. Trial-eligible TVT Registry patients were less likely to have ischemic cardiomyopathy (34.1% vs 60.8%) and more likely to have 4+ mitral regurgitation (79.4% vs 47.9%) compared with trial patients. We estimated that compared with medical therapy alone, MTEER in conjunction with other COAPT interventions (eg, optimization of medical therapy) in the trial-eligible population would result in 2-year absolute risk reductions of 17.0% for heart failure hospitalizations (95% CI: -28.7% to -5.7%) and 15.4% for all-cause death (95% CI: -26.6% to -5.2%), effect sizes similar to those estimated in the trial (P for difference between the trial and target populations >0.05 for both outcomes). The estimated treatment effect for heart failure hospitalizations in the broader treatment-candidate target population was also similar to that in the COAPT trial (P for difference = 0.90).</p><p><strong>Conclusions: </strong>Although COAPT trial patients had different baseline characteristics than patients undergoing MTEER in contemporary U.S. practice, we estimated that treatment effects would be similar had real-world patients received COAPT trial interventions, under the assumptions required for transportability (eg, conditional exchangeability across data sources, positivity of trial participation).</p>","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":" ","pages":"1704-1716"},"PeriodicalIF":22.3,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13334412/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148150402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medical Device Safety and Effectiveness: In Theory, There Is No Difference Between Theory and Practice…in Practice, There Is. 医疗器械的安全性和有效性:理论上,理论和实践没有区别……在实践中,有区别。
IF 22.3 1区 医学
Journal of the American College of Cardiology Pub Date : 2026-10-06 Epub Date: 2026-07-22 DOI: 10.1016/j.jacc.2026.06.019
Sreekanth Vemulapalli, Andrew Wang
{"title":"Medical Device Safety and Effectiveness: In Theory, There Is No Difference Between Theory and Practice…in Practice, There Is.","authors":"Sreekanth Vemulapalli, Andrew Wang","doi":"10.1016/j.jacc.2026.06.019","DOIUrl":"10.1016/j.jacc.2026.06.019","url":null,"abstract":"","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":" ","pages":"1717-1719"},"PeriodicalIF":22.3,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148549667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health Status Outcomes 7 Years After Transcatheter or Surgical Aortic Valve Replacement in Low-Surgical Risk Patients With Aortic Stenosis. 低手术风险主动脉瓣狭窄患者经导管或手术主动脉瓣置换术后7年的健康状况
IF 22.3 1区 医学
Journal of the American College of Cardiology Pub Date : 2026-10-06 Epub Date: 2026-07-29 DOI: 10.1016/j.jacc.2026.06.022
Michael I Brener, David J Cohen, Susheel K Kodali, Rebecca T Hahn, Vinod H Thourani, Raj R Makkar, Philippe Pibarot, Xiao Yu, Bradley Lubich, Michael J Mack, Martin B Leon, Suzanne V Arnold
{"title":"Health Status Outcomes 7 Years After Transcatheter or Surgical Aortic Valve Replacement in Low-Surgical Risk Patients With Aortic Stenosis.","authors":"Michael I Brener, David J Cohen, Susheel K Kodali, Rebecca T Hahn, Vinod H Thourani, Raj R Makkar, Philippe Pibarot, Xiao Yu, Bradley Lubich, Michael J Mack, Martin B Leon, Suzanne V Arnold","doi":"10.1016/j.jacc.2026.06.022","DOIUrl":"10.1016/j.jacc.2026.06.022","url":null,"abstract":"<p><strong>Background: </strong>Transcatheter aortic valve replacement (TAVR) results in early improvements in health status outcomes relative to surgical aortic valve replacement (SAVR) in low-surgical risk patients with symptomatic severe aortic stenosis. However, long-term data comparing the detailed health status outcomes of these 2 treatments are lacking.</p><p><strong>Objective: </strong>The purpose of this study was to compare long-term health status outcomes between TAVR and SAVR in low-risk patients and explore heterogeneity of treatment effect.</p><p><strong>Methods: </strong>The PARTNER 3 (Placement of Aortic Transcatheter Valves) trial randomized patients with severe aortic stenosis and low surgical risk 1:1 to TAVR with a balloon-expandable valve vs SAVR. Health status was evaluated with the Kansas City Cardiomyopathy Questionnaire (KCCQ) and Short Form-36 Heath Survey at baseline and 1 month, 6 months, and annually from years 1 to 7. Between treatment group differences in health status scores over time were examined with mixed effects models for repeated measures adjusted for baseline.</p><p><strong>Results: </strong>The analytic cohort included 943 patients enrolled in the PARTNER 3 trial who had baseline KCCQ assessments and underwent their assigned procedure (494 TAVR, 449 SAVR; mean age: 73.5 ± 5.9 years; 69.2% men; mean Society of Thoracic Surgeons-Predicted Risk of Mortality: 1.9% ± 0.6%; mean KCCQ-overall summary [KCCQ-OS] score: 70.9 ± 20.5). TAVR and SAVR both resulted in significant improvements in KCCQ and Short Form-36 Heath Survey summary scores relative to baseline through 7-year follow-up. KCCQ-OS scores were substantially higher at 1 month after TAVR vs SAVR (mean treatment difference: +16.2 points; 95% CI: 14.3-18.1) and remained modestly higher through 2 years of follow-up (mean difference at 2 years: +1.9 points; 95% CI: 0.2-3.7), but there were no significant between-group differences in years 3-7. At 7 years, ∼60% of patients in both treatment groups had an excellent outcome (alive, KCCQ-OS ≥75; no KCCQ-OS decline ≥10 from baseline).</p><p><strong>Conclusions: </strong>Patients with severe aortic stenosis at low surgical risk had substantial improvement in patient-reported health status with either TAVR or SAVR that was sustained through 7 years. Patients had earlier recovery with TAVR, but health status outcomes after 2 years were similar between treatment groups. (PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis; NCT02675114).</p>","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":" ","pages":"1690-1700"},"PeriodicalIF":22.3,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148620191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Estimating Redo Aortic Valve Replacement After TAVR: Kaplan-Meier vs Cumulative Incidence. 估计TAVR术后重做主动脉瓣置换术:Kaplan-Meier vs累积发生率。
IF 22.3 1区 医学
Journal of the American College of Cardiology Pub Date : 2026-10-06 Epub Date: 2026-08-05 DOI: 10.1016/j.jacc.2026.06.029
Harun Kundi, Graeme Hickey, David J Cohen, Martin B Leon, Jeffrey J Popma
{"title":"Estimating Redo Aortic Valve Replacement After TAVR: Kaplan-Meier vs Cumulative Incidence.","authors":"Harun Kundi, Graeme Hickey, David J Cohen, Martin B Leon, Jeffrey J Popma","doi":"10.1016/j.jacc.2026.06.029","DOIUrl":"10.1016/j.jacc.2026.06.029","url":null,"abstract":"","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":" ","pages":"1724-1726"},"PeriodicalIF":22.3,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148673811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aortic Valve Replacement in Women of Reproductive Age. 育龄妇女主动脉瓣置换术。
IF 22.3 1区 医学
Journal of the American College of Cardiology Pub Date : 2026-10-06 Epub Date: 2026-07-01 DOI: 10.1016/j.jacc.2026.05.024
Ruixin Lu, Magnus Dalén, Michael Dismorr, Natalie Glaser, Ulrik Sartipy
{"title":"Aortic Valve Replacement in Women of Reproductive Age.","authors":"Ruixin Lu, Magnus Dalén, Michael Dismorr, Natalie Glaser, Ulrik Sartipy","doi":"10.1016/j.jacc.2026.05.024","DOIUrl":"10.1016/j.jacc.2026.05.024","url":null,"abstract":"","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":" ","pages":"1720-1723"},"PeriodicalIF":22.3,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148361335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding the Cost of Microaxial Flow Pump Use in Patients With STEMI-Cardiogenic Shock. 了解stemi心源性休克患者使用微轴流泵的成本。
IF 22.3 1区 医学
Journal of the American College of Cardiology Pub Date : 2026-10-05 DOI: 10.1016/j.jacc.2026.09.030
Sanket S Dhruva, Kushal T Kadakia, David J Cohen, Jason H Wasfy
{"title":"Understanding the Cost of Microaxial Flow Pump Use in Patients With STEMI-Cardiogenic Shock.","authors":"Sanket S Dhruva, Kushal T Kadakia, David J Cohen, Jason H Wasfy","doi":"10.1016/j.jacc.2026.09.030","DOIUrl":"https://doi.org/10.1016/j.jacc.2026.09.030","url":null,"abstract":"","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":" ","pages":""},"PeriodicalIF":22.3,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149182594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书